FDA Approved: NAFCILLIN — Supplemental Application (Baxter Healthcare Corporation)

View source ↗

Summary

FDA approved a supplemental application for Nafcillin submitted by Baxter Healthcare Corporation under NDA 050655.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacteremia
• Endocarditis
• Osteomyelitis
• Skin and Soft Tissue Infections
• Staphylococcal Infections

Drugs mentioned

• Nafcillin (Unipen) (nafcillin)

Snippet

SUPPL AP for NAFCILLIN (NAFCILLIN)